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STUDY QUESTION: Can anti-Müllerian hormone (AMH) automated immunoassays (Elecsys® and Access) be used interchangeably as a
companion diagnostic for individualisation of follitropin delta dosing?
SUMMARY ANSWER: The Access assay gives systematically higher AMH values than the Elecsys® assay which results in over 29% of
women being misclassiﬁed to a different follitropin delta dose.
WHAT IS KNOWN ALREADY: Follitropin delta is the ﬁrst gonadotrophin to be licenced with a companion diagnostic, the Roche
Elecsys® AMH Plus assay. Alternative automated AMH assays including the Beckman Coulter Access immunoassay are considered to provide
similar results, but clariﬁcation of their suitability as an off-licence companion diagnostic for follitropin delta is required.
STUDY DESIGN, SIZE, DURATION:We systematically searched the existing literature for studies that had measured AMH using both
automated assays in the same cohort of women. Individual paired patient data were acquired from each author and combined with unpub-
lished data.
PARTICIPANTS/MATERIALS, SETTING, METHODS: We identiﬁed ﬁve eligible prospective published studies and one additional
unpublished study. A 100% response from the authors was achieved. We collected paired AMH data on samples from 848 women. Passing–
Bablok regression and Bland–Altman plots were used to compare the analytical performance of the two assays. The degree of misclassiﬁca-
tion to different treatment categories was estimated should the Access AMH be used as a companion diagnostic instead of the Elecsys AMH
in determining the dosing of follitropin delta.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
MAIN RESULTS AND THE ROLE OF CHANCE: The Passing–Bablok regression shows a linear relationship (Access = −0.05 + 1.10 ×
Elecsys). The Access assay systematically gave higher values by an average of 10% compared with the Elecsys assay (slope = 1.10, 95% CI: 1.09 to 1.12).
The average of the difference between the two assays was 2.7 pmol/l. The 95% limits of agreement were −11.7 to 6.3. Overall 253 (29.3%) women
would have received an inappropriate follitropin delta dose if the Beckman Coulter Access assay was used. Speciﬁcally, a substantial proportion of
women (ranging from 49% to 90% depending on the AMH category) would receive a lower dose of follitropin delta based on the Access AMH assay.
Up to 10% (ranging from 2.5% to 10%) of women with high ovarian reserve would have been misclassiﬁed to a greater dose of follitropin delta based on
the Access AMH assay.
LIMITATIONS REASONS FOR CAUTION:We compared the values of the two principal automated assays, extrapolation of our ﬁnd-
ings to other automated AMH assays would require similar comprehensive examination.
WIDER IMPLICATIONS OF THE FINDINGS: An international standard for the calibration of the automated AMH assays is warranted
to facilitate efﬁcient use of AMH as a companion diagnostic. The variable calibration of alternative automated AMH assays may adversely
impact on the performance of the follitropin delta dosing algorithm.
STUDY FUNDING/COMPETING INTEREST(S): No formal funding has been received for this study. SI is funded by a UK Medical
Research Council skills development fellowship (MR/N015177/1). SMN has received speakers fees, travel to meetings and participated in
advisory Boards for Beckman Coulter, IBSA, Ferring Pharmaecuticals, Finox, Merck Serono, Merck and Roche Diagnostics. SMN has received
research support from Ansh laboratories, Beckman Coulter, Ferring Pharmaceuticals and Roche Diagnostics.
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Introduction
Personalised stimulation protocols for assisted conception that
account for patients’ characteristics and prognostic biomarkers to
attain an ovarian optimal response have been the clinical vision in
reproductive medicine (Nelson, 2013; La Marca and Sunkara, 2014;
Iliodromiti et al., 2015). In other clinical ﬁelds, the use of a companion
diagnostic has been the hallmark of personalised medicine, and for-
mally extends the role of a speciﬁc biomarker, measured in an explicit
way, to guide treatment. The Food and Drug Administration (FDA)
and European Medicines Authority (EMA) deﬁne a companion diag-
nostic as a medical device, often an in vitro device, which provides
information that is essential for the safe and effective use of a corre-
sponding drug or biological product (FDA, 2017). As such the use of
an explicit companion diagnostic with a particular therapeutic product
is stipulated in the instructions for use in the labelling of both the diag-
nostic device and the corresponding therapeutic product. This is to
ensure that a result provided by an alternative provider does not result
in treatment decisions that may not be optimal.
A recent randomised controlled phase 3 trial has conﬁrmed the efﬁ-
cacy of individualised dosing of the gonadotrophin, follitropin delta, for
controlled ovarian hyperstimulation. Pharmacokinetic and pharmaco-
dynamic simulation facilitated development of an individualised dosing
algorithm for follitropin delta incorporating body weight, which inﬂu-
ences drug exposure, and pre-treatment anti-Müllerian hormone
(AMH) levels, which predict ovarian response. The dosing algorithm is
speciﬁc for follitropin delta and is designed to maintain ongoing preg-
nancy rates and reduce the risk of extreme ovarian responses (Nyboe
Andersen et al., 2017). AMH as determined on the Roche Elecsys
automated platform was a critical component of the individualised dos-
ing algorithm, led to this assay being incorporated into the licencing of
this novel drug as the speciﬁed companion diagnostic.
The optimal performance and stability of automated AMH assays over
previous manual assays is well recognised (Li et al., 2016; Pigny et al., 2016),
with many clinicians assuming that the values derived from the two most
common automated assays, namely, the Elecsys® AMH assay (Roche
Diagnostics International Ltd) and the Access AMH assay (Beckman
Coulter Diagnostics) are interchangeable. Small single-centred studies have
demonstrated almost identical values of AMH in the same samples mea-
sured in both assays (Tadros et al., 2016), while others have suggested that
the Access determined AMH values were 5–15% higher than that mea-
sured by the Elecsys system (Nelson et al., 2015; Li et al., 2016; Pigny et al.,
2016). It is unclear whether evidence of disagreement between the two
diagnostic methods may increase with larger sample number, with a wider
distribution of AMH and whether this discordance has any clinical implica-
tions. The aims of our study were to summarise the available evidence,
compare the performance of the two automated assays in a wider range of
women and determine whether the Access AMH assay would have strati-
ﬁed women to different dosing categories of follitropin delta compared
with the Elecsys® AMH assay, which is the licenced companion diagnostic
of choice.
Methods
Data acquisition
We searched the literature for studies on AMH and automated assays. A
systematic search was performed in Medline, Embase and Pubmed up to
December 2016. Keywords used were synonyms for AMH (anti-Müllerian
hormone or Müllerian inhibiting substance) and relevant to automated assays
(automated assay or Elecsys® or Access). All titles and abstracts were evalu-
ated for eligibility by two authors (SI and SMN). Potentially eligible papers
were read in full and relevant papers were selected. Eligible studies were
studies that had measured AMH using both Elecsys® and Access automated
assays in the same cohort of women. Reviews and case reports were
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excluded. There was no language restriction. In the identiﬁed studies, AMH
was measured in serum samples collected from women of reproductive age
using standard procedures and cryopreserved before measurement. The
assays were not necessarily performed simultaneously.
All authors of the selected papers were informed of the individual
patient data (IPD) protocol and invited to share their data. After data
acquisition, data were transferred into a single spreadsheet. Unpublished
data (from personal communication) were included in the spreadsheet.
AMH values were converted to pmol/l (ng/ml = 7.14 pmol/l).
Inconsistencies and invalid values were checked with the original authors.
Statistical analysis
Comparisons between the two methods were assessed using Bland–Altman
plots and Passing–Bablok regression. The 95% limits of agreement in the
Bland–Altman plot assume no bias between the two methods and were
assessed by visualisation. Passing–Bablok regression was used to describe the
relationship between the two methods with the Elecsys® assay being con-
sidered as the gold standard as it has already been evaluated and licensed as
the companion diagnostic for follitropin delta (Nyboe et al., 2016). Passing–
Bablok regression does not assume freedom of variables from error, nor does
it make any assumptions about the distribution of the data and hence it may be
less inﬂuenced by outliers. The percentage of women that would have been
stratiﬁed to a different dose of follitropin delta based on the AMH value mea-
sured with the Access rather than the Elecsys® assay were estimated. All statis-
tics were performed using Stata v14.1 (StataCorp, Texas, USA).
Results
Figure 1 shows the ﬂow chart of the search strategy. We selected ﬁve
published studies (Nelson et al., 2015; van Helden and Weiskirchen,
2015; Li et al., 2016; Pigny et al., 2016; Tadros et al., 2016) that fulﬁlled
our inclusion criteria. All authors responded to our request to share
their raw data. We also included data from 61 women from personal
correspondence with two of the co-authors (CF, RF). Supplemental
data Table SI shows the main characteristics of the studies/cohorts
included in our summary analyses.
In total, we had AMH values for 861 women, of whom 848 had
paired values measured with both assays. Supplementary data
Figure S1 demonstrates the distribution of AMH values for each assay,
with median 14.9 pmol/l (IQR: 6.6–28.2, range 0.07–232.6) for
Elecsys® assay as compared to 17.0 pmol/l (IQR: 7.5–31.9, range
0.05–247.4) for Access assay (P < 0.001). Figures 2 and 3 show the
Passing–Bablok regression and Bland–Altman plot comparing the two
assays across the range of AMH values. The Passing–Bablok regression
shows a linear relationship (Access = −0.05 + 1.10 × Elecsys) with
minimal visual disparity between the two assays. However, the Access
assay systematically gave higher values by an average of 10% compared
with the Elecsys assay (slope = 1.10, 95% CI: 1.09–1.12). The Bland–
Altman plot suggests that the discordance between the two assays
was consistent with increasing values of AMH. On average, Access
assay measured on average 2.7 pmol/l (bias) greater values than the
Elecsys® assay based on a median concentration of circa 15 pmol/l.
The 95% limits of agreement were −11.7 to 6.3.
Table I presents the percentage of patients that would have been
classiﬁed to a different treatment category of follitropin delta should
the AMH have been measured with the Access assay instead of the
Elecsys® assay. In total, 253 (29.3%) women would have been classi-
ﬁed to a different follitropin delta dose based on use of the Access
assay as compared to the Roche assay. Speciﬁcally a substantial pro-
portion of women (ranging from 50% to 90% depending on the AMH
Figure 1 Flow chart of search strategy and data combination.
Figure 2 Passing–Bablok regression line with 95% conﬁdence inter-
vals of Elecsys and Access Assays. Passing–Bablok regression line with
95% conﬁdence intervals Access = −0.05 + 1.10 (95% CI: 1.09–1.12) ×
Elecsys. The dots represent the paired values of AMH.
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category) would have been given a lower dose of follitropin delta
based on the Access assay. Although the overall values are higher with
the Access assay, up to 10% (ranging from 2.9% to 10%) of women
with high ovarian reserve would have been misclassiﬁed to a greater
dose of follitropin delta based on the Access assay.
Discussion
The Elecsys® AMH Plus immunoassay by Roche is the ﬁrst companion
diagnostic that has been approved for individualisation of gonadotropin
dosing in reproductive medicine. In accordance with FDA and EMA
guidance on companion diagnostics, this immunoassay is stipulated in
the EMA licence of follitropin delta. Herein, we report evidence from a
large sample of women (n = 848) with a wide distribution of AMH
values in whom values obtained by an alternative automated AMH
assay, the Beckman Coulter Access assay, were systematically higher
than that by the Elecsys® assay, by an average of 10%. This apparently
modest discordance would result in an overall 29% of women being
classiﬁed to an incorrect follitropin delta dose.
Reproductive medicine clinicians are accustomed to interpreting a
range of biomarkers to guide clinical decision-making. However, the
era of companion diagnostics formalises this relationship, with a spe-
ciﬁc companion diagnostic stipulated in the licencing and prescribing
guidance of a drug. As such, regulatory authorities now recommend
the joint development of therapeutic products and diagnostic devices
(FDA, EMA 2017). As the results from the diagnostic device/test are
essential for patient treatment, health care professionals must be able
to rely on those results. Imprecise performance of an in vitro diagnostic
(IVD) could have substantial therapeutic consequences, and lead to
the administration of inappropriate therapy hence the strict drug licen-
cing conditions with the speciﬁc IVD test named.
Individualised ovarian stimulation with follitropin delta relies on very
narrow categories of AMH to stratify women to the appropriate
gonadotropin dose to achieve a target ovarian response of 8–14
oocytes (Arce et al., 2014; Bosch et al., 2015; Nyboe Andersen et al.,
2017). That a large number of women would be classiﬁed differently if
an alternative assay was used, in part reﬂects the small AMH categor-
ies that were used in the original dosing algorithm. Classifying women
to a lower gonadotrophin dose because of difference in calibration of
the Access AMH assay would likely lead to a systematic shift in the
ovarian response to the left with the potential for inadequate follicular
development and subsequent lower live-birth rates (Sunkara et al.,
2011; Steward et al., 2014). Whereas, a small but clinically substantial
proportion of women with high ovarian reserve may be stratiﬁed to
receive a higher gonadotrophin dose based on the Access AMH assay,
with an inherent increased risk of iatrogenic ovarian hyperstimulation
syndrome or cycle cancellation (Steward et al., 2014). Both scenarios,
albeit requiring conﬁrmation from off-licence studies examining the
clinical implications of inappropriate follitropin delta dosing, counteract
.............................................................................................................................................................................................
Table I Follitropin delta dosing algorithm and risk of dosing misclassiﬁcation.
Serum AMH
(pmol/l) based
on Elecsys assay†
Daily dose
of Follitropin
delta†
Number of women
based on Elecsys
assay (N = 848)
N (%) misclassiﬁed to greater
treatment category (lower
dose) based on Access assay*
N (%) misclassiﬁed to lower
treatment category (higher
dose) based on Access assay*
<15 12 μg 426 38 (8.9) –
15–16 0.19 μg/kg 43 26 (60.4) 2 (4.7)
17 0.18 μg/kg 19 17 (89.5) 0 (0)
18 0.17 μg/kg 25 21 (84.0) 1 (4.0)
19–20 0.16 μg/kg 33 20 (60.6) 3 (9.1)
21–22 0.15 μg/kg 35 25 (71.4) 1 (2.9)
23–24 0.14 μg/kg 20 16 (80.0) 2 (10.0)
25–27 0.13 μg/kg 31 22 (71.0) 1 (3.2)
28–32 0.12 μg/kg 47 28 (59.6) 0 (0)
33–39 0.11 μg/kg 51 25 (49.0) 2 (3.9)
≥40 0.10 μg/kg 118 – 3 (2.5)
†Follitropin delta dosing algorithm as in provided in the prescribing information. All AMH values <15 pmol/l receive 12 μg irrespective of body weight in ﬁrst cycle. For AMH values
above ≥15 pmol/l the dose is per kg body weight.
*Number and % of women misclassiﬁed for each AMH dosing strata
Figure 3 Bland–Altman plot of Elecsys and Access Assay. Mean dif-
ference −2.7 pmol/l (dashed line) with 95% conﬁdence intervals
(−11.7 to 6.3) (dotted lines).
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the value of biomarker-tailored personalised treatment with potential
detrimental effects. In addition, both diminished ovarian response and
iatrogenic hyperstimulation due to inappropriate follitropin delta dos-
ing may be associated with ﬁnancial implications for patients and state
funders. Standardisation of the automated AMH assays or validation of
the dosing algorithm to the technical characteristics of other auto-
mated assays is critical to ensure the successful transition to individua-
lised stimulation protocols.
The underlying cause for the discordance between assays is
unclear. The systematic difference across the range of AMH values
and the association between the two assays suggest a discordance
in calibration rather than assay technical characteristics or linearity.
The Elecsys assay has been standardised via sample value transfer
from the Gen II assay under the unmodiﬁed protocol using an aged
serum panel (Gassner and Jung, 2014). The Access AMH assay was
harmonised with the Gen II assay under the modiﬁed protocol
using frozen samples (Demirdjian et al., 2016). These AMH con-
centrations were then transferred to Access AMH mean signal
counts to assign values to reference calibrators prepared with
recombinant total AMH (Immunotech (IOT)) in HEPES buffer using
three reagent pack lots (Demirdjian et al., 2016). That the Access
assay currently utilises a recombinant AMH for manufacturing of
calibration standards, may potentially contribute to less batch to
batch variability and maintenance of the observed discordance. An
universal recombinant based standard adopted by all manufac-
turers for the calibration of the automated AMH assays will be crit-
ical to facilitate individualisation of ovarian stimulation. This will
particularly be the case for follitropin delta, but will also apply to
universal interpretation of AMH results for selection of alternative
gonadotropin doses.
Our study has several strengths, it is the largest study comparing
the technical performance of the two automated assays. We com-
bined existing with unpublished data by implementing an IPD
protocol to show the limits of agreements of the two assays in a
wider range of AMH values than each single study. This range of
clinically relevant values enabled us to provide a robust estimate of
the discordance between the two assays that may not be detected
in single centre studies examining speciﬁc sub-groups of women.
The systematic search of the literature, the 100% response rate
and inclusion of unpublished data minimised the risk of publication
bias. This is the ﬁrst study that evaluated the discordance in the
two automated assays and its impact in dosing misclassiﬁcation and
underscored the need for universal standards in the calibrations of
the automated assays. All included studies used a prospective
design and implemented the manufacturer analytical guidance mini-
mising the between study heterogeneity. Automated assays show
substantial pre-analytical stability to different room temperatures,
freezing and storage conditions (Demirdjian et al., 2016) overcom-
ing the limitation of inter-laboratory measurements. We do how-
ever acknowledge several limitations; we only compared two of
the most frequently used automated assays rather than all of the
available automated assays, but for many geographical areas includ-
ing Europe, Australia and the USA the Biomerieux assay will not be
available. We have not assessed the effect of the intra-assay coefﬁ-
cient of variation (CV), and accept that repeat measurements on
the same sample may have resulted in misclassiﬁcation, but the
inter assay CV has been reported by several multi-centre studies
as <5% (Gassner and Jung, 2014; Anckaert et al., 2016).
Undoubtedly, the need for universal calibration using international
standards applies to all automated assays.
Conclusion
The two most widely used automated AMH assays have modest but sys-
tematic differences in their values. The clinical implication of this is most
striking for a novel individualised dosing algorithm based on a licenced
companion diagnostic assay, with a large number of women at risk of
inappropriate dosing if an alternative automated AMH assay is used.
Supplementary data
Supplementary data are available at Human Reproduction online.
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